15.25 -0.25 (-1.61%)
After hours: 7:59PM EST
|Bid||12.28 x 500|
|Ask||16.50 x 100|
|Day's Range||15.25 - 16.36|
|52 Week Range||6.73 - 16.36|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
CEO of pharmaceutical company Mylan, Heather Bresch, sits down the Yahoo Finance's Andy Serwer and Jen Rogers to discuss what the future holds for the drug company.
This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on January 10. Over the last one-month, outflows of investor capital in ETFs holding ARRY totaled $5.10 billion.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ARRY totaled $3.32 billion.
Boulder drug development company Array BioPharma has spun off its research into a treatment for a rare degenerative heart disease into a separate company. Array BioPharma (ARRAF), in a filing to the U.S. Securities & Exchange Commission on Chistmas Eve, revealed that it had contributed intellectual property, inventory, equipment, clinical trial data and other material about its experimental cardiomyopathy drug to a subsidiary it’s calling Yarra Therapeutics. The oral drug, known only as Array 797, is being developed to treat “lamin A/C-related dilated cardiomyopathy,” which is caused by a specific gene mutation.
Understanding Array BioPharma Inc’s (NASDAQ:ARRY) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...
A Relative Strength Rating upgrade for Array Biopharma shows improving technical performance. Will it continue?
CEO of Array Biopharma Inc (NASDAQ:ARRY) Ron Squarer sold 819,671 shares of ARRY on 12/19/2017 at an average price of $10.86 a share.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Array BioPharma, Inc. Here are 5 ETFs with the largest exposure to ARRY-US. Comparing the performance and risk of Array BioPharma, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Array BioPharma, Inc. a score of 25. Our analysis is based on comparing Array BioPharma, Inc. with the following peers – Celgene Corporation, Amgen Inc., Cascadian Therapeutics Inc., Eli Lilly and Company, Novartis AG Sponsored ADR, Astrazeneca PLC Sponsored ADR and Onconova Therapeutics Inc. (CELG-US, AMGN-US, CASC-US, ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Array BioPharma, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish ... Read more (Read more...)